New injectable medicine for children with moderate to severe eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new medicine (called 611) given as an injection to children with moderate-to-severe eczema that hasn't improved with creams. The goal is to see if it can reduce itching and clear the rash.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 2 and 11 years old and weigh at least 33 pounds (15 kg).
- Your child must have had eczema for at least 3 to 6 months (depending on age) and it must be considered moderate to severe.
- Your child's eczema must cover at least 10% of their body, and they must have a history of not responding well to prescription creams or ointments.
- Your child must have significant itching (at least 4 out of 10 on an itch scale) and be willing to use moisturizers twice a day.
- Your child must not have certain infections (like tuberculosis or hepatitis) or other serious medical conditions.
- Your child must not have used certain other eczema medications or live vaccines recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injectable medicine (611) for teenagers with moderate to severe eczema that hasn't been helped enough by creams. It aims to see if the drug can safely reduce itching and skin symptoms.
This study tests a new medicine, MG-K10, given as an injection, to see if it can reduce eczema symptoms like itching and skin rash in teenagers. It's for teens whose eczema is not well controlled with topical treatments.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
This trial tests a new injectable medicine called FB825 for people with moderate to severe eczema that hasn't improved enough with standard creams. The study aims to see if FB825 can reduce itching and skin symptoms safely.
This study tests a new medication (IBI3033) for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. The goal is to see if it's safe and effective in reducing symptoms like itching and rash.
This study tests a new injectable medication (HXN6005) for people with moderate-to-severe eczema that hasn't been controlled by topical treatments. The goal is to see if the drug is safe and effective in reducing eczema symptoms.
Hear when a new Dermatitis, Atopic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.